Related Content
- Big Molecule WatchApril 18, 2024
Genentech and Dr. Reddy’s Settle BPCIA Rituximab Litigation
- Big Molecule WatchApril 17, 2024
MDL Panel Grants Transfer of Aflibercept BPCIA Case
- Big Molecule WatchApril 11, 2024
FDA Approves BMS and J&J CAR-T Cell Therapies for the Earlier Treatment of Multiple Myeloma
- Big Molecule WatchApril 9, 2024
FDA Approves New Indication for AstraZeneca and Daiichi Sankyo’s Cancer Drug ENHERTU
- Big Molecule WatchMarch 29, 2024
REGENXBIO and Sarepta Agree to Stay Litigation Pending Outcome of Sarepta’s IPR Petition
- Big Molecule WatchMarch 28, 2024
Fresenius Kabi and Formycon Reach Settlement Agreement for Ustekinumab Biosimilar Candidate in Europe and Canada
- Big Molecule WatchMarch 28, 2024
FDA Approves First Gene Therapy to Treat Children with Metachromatic Leukodystrophy
- Big Molecule WatchMarch 27, 2024
Biden Administration Proposes Biosimilar Substitution Without Interchangeability
- Awards and RankingsSeptember 25, 2023
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year
- Awards and RankingsOctober 4, 2022
LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences
- Press ReleaseNovember 17, 2021
Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.
- Awards and RankingsOctober 26, 2021
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year
- Press ReleaseJune 28, 2021
Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson
- EventsDecember 5, 2020
China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?
- Awards and RankingsOctober 5, 2020
Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year
- Speaking EngagementsSeptember 23, 2020
ACI's 11th Summit on Biosimilars & Innovator Biologics